Once daily multiple sclerosis treatment approved for use in Scotland
The Scottish Medicines Consortium has approved Zeposia® (ozanimod) for use in relapsing remitting multiple sclerosis patients.
List view / Grid view
The Scottish Medicines Consortium has approved Zeposia® (ozanimod) for use in relapsing remitting multiple sclerosis patients.
The new pathway developed by NICE for medicines to go from clinical trials to NHS patients is now in action.
The Kymriah (tisagenlecleucel) treatment has received a positive appraisal from the Scottish Medicines Consortium, after EMA approval last year.
The SMC has approved a drug, called rivaroxaban, that targets Factor Xa to treat those with coronary artery disease (CAD)...
The Scottish Medicines Consortium has published advice accepting three new medicines for routine use...
NICE has released a Final Appraisal Document recommending Nexavar for the treatment of patients with advanced hepatocellular carcinoma...
The Scottish Medicines Consortium (SMC) has made a final decision to turn down Perjeta (pertuzumab) for routine NHS funding for first line use in women whose HER2-positive breast cancer has returned to the breast but is inoperable, or where it has spread to other parts of the body.
The SMC endorses routine prescribing across NHS Scotland of Ipsen’s cabozantinib, offering a new therapy option to help battle kidney cancer.
14 December 2016 | By Niamh Louise Marriott, Digital Editor
Prostate cancer can become resistant to hormone therapy and continue to grow despite treatment. Jevtana (cabazitaxel) is the only remaining chemotherapy...
11 October 2016 | By Niamh Louise Marriott, Digital Content Producer
This recommendation means that patients in Scotland will become the first in the UK to be treated with nivolumab on the NHS...
29 September 2016 | By Niamh Louise Marriott, Digital Content Producer
NICE are recommending it as an option to treat adults with active ankylosing spondylitis (AS) who have responded inadequately to conventional therapy...
18 August 2016 | By The National Institute for Health and Care Excellence (NICE)
When initially reviewed, the committee concluded that the drug was too expensive compared to the current standard of care. Pfizer submitted further evidence, including a new patient access scheme that provided the drug at a lower price alongside revised analyses, which the committee then concluded could now be considered value…
8 August 2016 | By Bristol-Myers Squibb
The SMC initially refused access to nivolumab for Scottish patients, having taken a different view to the National Institute for Health and Care Excellence (NICE), which approved it to treat patients in England and Wales. However, following a review of additional evidence, the SMC decision has been reversed, bringing access…
11 July 2016 | By Victoria White, Digital Content Producer
The SMC has accepted five new medicines for routine use in NHS Scotland including lung cancer treatments nivolumab and crizotinib...
The Scottish Medicines Consortium (SMC) has rejected Kalydeco (ivacaftor) and Orkambi (lumacaftor-ivacaftor) for the treatment of cystic fibrosis.